Status:
COMPLETED
Efficacy of Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation in Hemodialysis Patients
Lead Sponsor:
University of Illinois at Urbana-Champaign
Conditions:
Complication of Dialysis
Chronic Kidney Disease
Eligibility:
All Genders
30-80 years
Phase:
NA
Brief Summary
The purpose of this study is to examine the effect of 6 months of daily beta-hydroxy beta-methylbutyrate (HMB) supplementation on the physical function and the health of bones, arteries and heart in h...
Detailed Description
Patients with renal failure receiving hemodialysis experience an increased rate of skeletal muscle protein catabolism which is associated with a number of co-morbid conditions including declines in mu...
Eligibility Criteria
Inclusion
- Must be receiving hemodialysis treatment.
- Must be willing to be randomized to HMB or placebo for 6 months
- Must receive physician clearance to participate
Exclusion
- Bodyweight \> 350 lbs
- Currently taking an HMB supplement or HMB containing products (eg. Ensure)
Key Trial Info
Start Date :
November 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2016
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT01837238
Start Date
November 1 2012
End Date
May 1 2016
Last Update
October 31 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Illinois
Urbana, Illinois, United States, 61822